| 1.6 -0.2 (-11.11%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.01 | 1-year : | 3.51 |
| Resists | First : | 2.57 | Second : | 3.01 |
| Pivot price | 1.27  |
|||
| Supports | First : | 1.32 | Second : | 0.55 |
| MAs | MA(5) : | 1.9  |
MA(20) : | 1.11 |
| MA(100) : | 0.9 |
MA(250) : | 2.09 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 62.2 |
D(3) : | 67.8 |
| RSI | RSI(14): 62.1 |
|||
| 52-week | High : | 10 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GNTA ] has closed below upper band by 36.9%. Bollinger Bands are 476.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.88 |
| Low: | 1.55 - 1.56 | 1.56 - 1.58 |
| Close: | 1.58 - 1.6 | 1.6 - 1.62 |
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Fri, 05 Jun 2026
GNTA Stock Chart | GENENTA SCIENCE SPA - ADR (NASDAQ:GNTA) - ChartMill
Mon, 01 Jun 2026
GNTA Stock Explodes On Volume As Traders Scan Biotech Charts - StocksToTrade
Mon, 01 Jun 2026
GNTA Stock Sees Volatile Spike As Traders Eye Key Levels - timothysykes.com
Fri, 29 May 2026
Genenta Science (GNTA) takes full control by acquiring remaining 80.5% of A.T.C. - Stock Titan
Wed, 29 Apr 2026
Genenta Science to Close U.S. Subsidiary and Shift CFO to Consulting Role - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 44.5 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 63 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -38.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -4.22 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|